糖尿病患者腹主动脉瘤发生的危险因素
该研究对2009至2012年间接受健康筛查的50岁以上糖尿病患者随访至2019年12月31日,平均随访7.7年,共1913066名参与者中识别出6996例腹主动脉瘤。多因素分析显示年龄≥65岁、男性、吸烟、腹部肥胖及合并高血压、血脂异常、慢性肾脏病、心血管疾病与腹主动脉瘤风险升高相关,而饮酒、超重/肥胖、糖尿病病程较长及使用三种以上口服降糖药与风险降低相关。
要点
- 糖尿病患者中,年龄≥65岁、男性、吸烟史、腹部肥胖及合并心血管代谢疾病与腹主动脉瘤风险升高相关。
- 吸烟者风险随累积吸烟量增加而升高,当前吸烟≥20包年者风险最高(HR 2.40)。
- 使用二甲双胍、噻唑烷二酮类或磺脲类药物与腹主动脉瘤风险降低相关,但需进一步研究验证。
核心结论
- 尽管糖尿病与腹主动脉瘤风险降低相关,但合并心血管代谢疾病、腹部肥胖及有吸烟史的患者应意识到腹主动脉瘤风险升高。
- 需要进一步研究验证口服降糖药降低腹主动脉瘤风险的潜在用途。
研究设计与样本
- 研究为对2009至2012年间接受健康筛查的50岁以上糖尿病患者进行随访至2019年12月31日的队列研究。
- 共纳入1913066名参与者(55.3%为男性),平均随访7.7年,识别出6996例腹主动脉瘤。
- 采用Cox比例风险回归模型计算多因素风险比(HR)及95%置信区间(CI)。
主要发现
- 年龄≥65岁(HR 2.69;95% CI 2.55-2.83)、男性(HR 1.81;95% CI 1.69-1.94)与腹主动脉瘤风险升高相关。
- 吸烟者风险升高:既往吸烟≥20包年(HR 1.75;95% CI 1.61-1.89)、当前吸烟<20包年(HR 1.76;95% CI 1.59-1.94)、当前吸烟≥20包年(HR 2.40;95% CI 2.23-2.59)。
- 腹部肥胖(HR 1.30;95% CI 1.23-1.38)、高血压(HR 1.63;95% CI 1.53-1.73)、血脂异常(HR 1.35;95% CI 1.29-1.42)、慢性肾脏病(HR 1.52;95% CI 1.44-1.61)及心血管疾病(HR 1.71;95% CI 1.58-1.86)与风险升高相关。
- 大量饮酒(HR 0.67;95% CI 0.61-0.74)、少量饮酒(HR 0.78;95% CI 0.74-0.83)、超重(HR 0.87;95% CI 0.81-0.93)、肥胖(HR 0.81;95% CI 0.75-0.87)、糖尿病病程≥5年(HR 0.74;95% CI 0.70-0.78)及使用三种以上口服降糖药(HR 0.84;95% CI 0.79-0.90)与风险降低相关。
- 使用胰岛素与风险边缘性升高相关(HR 1.09;95% CI 1.00-1.18);二甲双胍(HR 0.95;95% CI 0.90-1.00)、噻唑烷二酮类(HR 0.87;95% CI 0.79-0.97)及磺脲类(HR 0.88;95% CI 0.83-0.93)与风险降低相关。
临床怎么用
- 作者认为,合并心血管代谢疾病、腹部肥胖及有吸烟史的糖尿病患者应意识到腹主动脉瘤风险升高。
- 作者建议,需要进一步研究验证口服降糖药降低腹主动脉瘤风险的潜在用途。
局限性
- 需要进一步研究验证口服降糖药降低腹主动脉瘤风险的潜在用途。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Although diabetes has been shown to be negatively associated with development of abdominal aortic aneurysm (AAA), patients with diabetes may still develop aneurysms. In this study, we examined risk factors for the development of AAA in patients with diabetes. METHODS: Adults >50 years of age with diabetes who underwent health screening between 2009 and 2012 were followed for incident AAA until December 31, 2019. Cox proportional hazard regression models were used to calculate multivariate hazard ratios (HRs) and 95% confidence intervals (CIs) for risk factors associated with AAA. RESULTS: Among 1,913,066 participants (55.3% men), 6996 AAA cases were identified during a mean follow-up of 7.7 years. Increased AAA risk was observed for age ≥65 years (HR, 2.69; 95% CI, 2.55-2.83), men (HR, 1.81; 95% CI, 1.69-1.94), smoking (former smoker ≥20 pack-years [PY]; HR, 1.75; 95% CI, 1.61-1.89; current smoker <20 PY; HR, 1.76; 95% CI, 1.59-1.94; current smoker ≥20 PY; HR, 2.40; 95% CI, 2.23-2.59), abdominal obesity (HR, 1.30; 95% CI, 1.23-1.38), and comorbidities, including hypertension (HR, 1.63; 95% CI, 1.53-1.73), dyslipidemia (HR, 1.35; 95% CI, 1.29-1.42), chronic kidney disease (HR, 1.52; 95% CI, 1.44-1.61), and cardiovascular disease (HR, 1.71; 95% CI, 1.58-1.86). Heavy (HR, 0.67; 95% CI, 0.61-0.74) and mild alcohol consumption (HR, 0.78; 95% CI, 0.74-0.83), overweight (HR, 0.87; 95% CI, 0.81-0.93) and obesity (HR, 0.81; 95% CI, 0.75-0.87), longer diabetes duration (≥5 years: HR, 0.74; 95% CI, 0.70-0.78), and using three or more oral hypoglycemic agents (OHA) (HR, 0.84; 95% CI, 0.79-0.90) were associated with decreased AAA risk, whereas insulin use was associated with a marginally increased risk (HR, 1.09; 95% CI, 1.00-1.18). Among the OHAs, metformin (HR, 0.95; 95% CI, 0.90-1.00), thiazolidinediones (HR, 0.87; 95% CI, 0.79-0.97), and sulfonylureas (HR, 0.88; 95% CI, 0.83-0.93) were associated with a decreased risk of AAA. CONCLUSIONS: Although diabetes is associated with decreased AAA risk, those with comorbid cardiometabolic diseases, abdominal obesity, and a smoking history should be aware of an increased AAA risk. Further studies are warranted to verify the potential use of OHAs for decreasing AAA risk.
引用
- Cho IY, Han K, Lee KN, et al. Risk factors for abdominal aortic aneurysm in patients with diabetes. J Vasc Surg. 2024. PMID: 39303864. doi:10.1016/j.jvs.2024.09.007
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。